By: R. Huddart PhD
Testicular germ cell tumours (TGCTs) are the most common cancer in men between the ages of 15 and 40 years. Luckily, the majority of these patients can expect to be cured. However, the optimal follow-up for patients after their initial management is still subject to debate. During a keynote lecture at the 2021 annual BMUC meeting, Prof Robert Huddart discussed some of the key aspects of this follow-up process.
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
